Ultomiris is a Intravenous Solution, Concentrate in the Human Prescription Drug category. It is labeled and distributed by Alexion Pharmaceuticals Inc.. The primary component is Ravulizumab.
Product ID | 25682-028_0584968e-282e-4a10-aa66-f0329d41f571 |
NDC | 25682-028 |
Product Type | Human Prescription Drug |
Proprietary Name | Ultomiris |
Generic Name | Ravulizumab |
Dosage Form | Solution, Concentrate |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2018-12-21 |
Marketing Category | BLA / BLA |
Application Number | BLA761108 |
Labeler Name | Alexion Pharmaceuticals Inc. |
Substance Name | RAVULIZUMAB |
Active Ingredient Strength | 1100 mg/11mL |
Pharm Classes | Complement Inhibitor [EPC],Complement Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2018-12-21 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
25682-022 | Ultomiris | ravulizumab |
25682-025 | Ultomiris | ravulizumab |
25682-028 | Ultomiris | ravulizumab |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
ULTOMIRIS 87713118 5716901 Live/Registered |
Alexion Pharmaceuticals, Inc. 2017-12-08 |